SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has ...

Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to DiffuseSandbox, its self-serve protein ...

BioDlink, a leading global contract development and manufacturing organization (CDMO), has released a white paper titled ...

Advanced Biomultifold Technology will further facilitate higher expression & production levels for Biologics in critical care / rare disease biologics (manufacturing), thus help to bring down the ...

Paras Biopharma extensive efforts have resulted in successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion ...